REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Northern Trust Corp

Northern Trust Corp cut its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 4.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 465,261 shares of the biotechnology company’s stock after selling 22,726 shares during the period. Northern Trust Corp owned about 0.94% of REGENXBIO worth $3,596,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in shares of REGENXBIO in the 4th quarter valued at about $54,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of REGENXBIO in the 4th quarter valued at about $79,000. Teacher Retirement System of Texas boosted its holdings in shares of REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,088 shares during the period. EntryPoint Capital LLC acquired a new position in shares of REGENXBIO in the 4th quarter valued at about $97,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of REGENXBIO by 442.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 10,714 shares during the period. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Stock Up 2.3%

Shares of NASDAQ:RGNX opened at $9.86 on Friday. REGENXBIO Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $15.91. The company has a market cap of $494.58 million, a PE ratio of -1.96 and a beta of 1.11. The company’s 50-day moving average price is $7.78 and its 200 day moving average price is $8.01.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. As a group, equities analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

Insiders Place Their Bets

In related news, Director Kenneth T. Mills sold 20,602 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now directly owns 475,103 shares in the company, valued at $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.79% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on RGNX shares. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a report on Tuesday, March 18th. Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. Wall Street Zen upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Raymond James assumed coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price objective on the stock. Finally, Morgan Stanley lifted their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and an average target price of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.